******Anthropic's massive raise, valuation leap, AI-biotech M&A, secondaries & infra deals** [climaxing]
Key Questions
What are the details of Anthropic's recent financing round?
Anthropic secured approximately $30 billion in financing at an implied $380 billion valuation, with $14 billion in revenue. It attracted $2 billion from investors amid OpenAI losing appeal. This reflects strong investor interest and secondary market frenzy.
What was the Coefficient Bio acquisition by Anthropic?
Anthropic confirmed a $400 million all-stock acquisition of AI-biotech startup Coefficient Bio, an acq-hire with fewer than 10 people (around $40M per engineer). This expands Anthropic's focus into life sciences and AI synergies. The deal involved Daydream cofounders and is part of broader M&A activity.
How is the secondary market reacting to Anthropic?
There is $2 billion in secondary demand with no sellers, contrasting with OpenAI's discount. This frenzy signals high valuation and investor enthusiasm. It contributes to Q4 IPO buzz at potentially $60 billion+.
What is the buzz around Anthropic's IPO?
Q4 IPO speculation is growing at a $60 billion+ valuation. This comes amid massive raises, M&A, and dominant LLM/infrastructure positioning. Syndicate, secondaries, and IPO path remain key open questions.
How does Anthropic's valuation compare to rivals like OpenAI?
Anthropic's $380 billion implied valuation positions it strongly, with deals like Broadcom boosting stock trends for AVGO. Comparisons highlight it against OpenAI, noting Anthropic's appeal in funding. This is part of ongoing AI rival analyses.
~$30B financing at ~$380B val, $14B rev; Broadcom/Google GW-scale TPU deal from 2027; $400M Coefficient Bio acq-hire; $2B secondary demand/no sellers; Q4 IPO buzz at $60B+. Dominant LLM/infra. Open: syndicate/secondaries/IPO, M&A.